Aim. To study the effect of obesity on the clinical and laboratory status of patients with CHF depending on polymorbidity and the variant of kidney damage.
Material and methods. The study included 176 patients with CHF aged 69.48±13.24 years. Patients were divided into 2 groups: the main – 78 patients with obesity I–III degree and the comparison group – 98 (normal or overweight). Venous blood was taken from all patients on the 1st-3rd day of hospitalization in order to determine the levels of creatinine, NGAL, cystatin C, NTproBNP, ST2 and their content was assessed depending on the presence and severity of obesity, the variant of kidney damage, and polymorbidity.
Results. In the studied sample, 44.32% of patients had obesity of I–III degrees. Every 2nd patient was diagnosed with obesity of the 1st degree, and almost every 3rd patient was diagnosed with obesity of the 2nd degree. 43.59% of patients with obesity had C3-5 CKD prior to the present hospitalization. In 37.18% of patients with obesity, proteinuria was determined, mainly of subnephrotic level. AKI was diagnosed in every 5th patient (23.29%), in patients with obesity mainly (63.16%) of 2–3 stages. During hospitalization, 2.84% of patients died. All the deceased developed AKI stage 2 or 3 in the background of C3-5 CKD. Patients with AKI had higher levels of all studied biomarkers (NGAL, cystatin C, NT-proBNP, ST2). According to our data, the presence of obesity is associated with the risk of developing AKI (OR=2.269, 95% CI 0.04–129.799) and the severity of AKI (OR=1.246, 95% CI 0.459–3.386), the frequency of hospitalization due to the development of ADHF (OR=1.52, 95% CI 0.666–3.472).
Conclusion. Timely diagnosis and treatment of obesity will reduce the risk of AKI and mortality, development and progression of CKD.

Keywords: ST2, polymorbidity, NGAL, NT-proBNP, cystatin C, creatinine, chronic heart failure, obesity